ALSO READGlenmark Pharma draws up capex of USD 300 mn over next 3 yrs Glenmark Pharma's Ankleshwar plant gets 4 FDA observations Glenmark Pharma gains after launching generic drug in US Glenmark Pharma gains after USFDA approval for Tretinoin capsules Glenmark Pharma tumbles as Q4 result miss market expectations
Its second oncology candidate to enter clinical trialsGlenmark Pharmaceuticals announced that the USFDA cleared the company's Investigational New Drug (IND) application to initiate a Phase 1 study of GBR 1342, a humanized, bispecific monoclonal antibody (bsAb) being studied for the treatment of multiple myeloma in patients who have received prior therapies. GBR 1342 is designed to activate the patient's immune system by redirecting immune cells towards tumor tissue, which may lead to targeted destruction of tumors. It is based on Glenmark's proprietary BEAT (Bispecific Engagement by Antibodies based on the T cell receptor) technology platform.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)